6120 RESULTS
Sort By:
RESEARCH NEWS 2023-09-29 Research News Earlier this year, a high-profile Science paper caused a stir with its claim that the brain has a fourth, previously unrecognized, meningeal membrane. Dubbed SLYM and containing Prox1+ cells, this membrane was proposed to divide the subarach
RESEARCH NEWS 2003-05-22 Research News The widely used psychiatric drug lithium, and other agents that inhibit glycogen synthase kinase-3 (GSK3), have been mentioned as possible Alzheimer's disease therapies for some time, primarily because GSK3 is one of several kinases kno
RESEARCH NEWS 2005-05-13 Research News A mixed bag of epidemiologic studies alternatively hold up and knock down the promise that widely prescribed cholesterol-lowering statin drugs might offer some protection against Alzheimer disease progression (see ARF related news story). La
COMMUNITY NEWS 2012-02-02 Community News See Q&A With Bengt Långström The ability to visualize fibrillar Aβ deposits in the brains of living people has been hailed as a breakthrough for Alzheimer’s disease research and differential diagnosis. Now, as the first of a suite of po
RESEARCH NEWS 2006-09-09 Research News A paper out today in Cell proposes a novel role for presenilins in calcium signaling—that of an ion channel. The work, from Ilya Bezprozvanny and colleagues at the University of Texas Medical Center at Dallas, shows that presenilins appear t
CONFERENCE COVERAGE 2008-08-07 Conference Coverage Of all clinical trials reported at the International Conference on Alzheimer’s Disease (ICAD) held 26-31 July in Chicago, one targeting the protein tau was the therapy du jour, both in terms of buzz among scientists and media coverage.
RESEARCH NEWS 2007-01-25 Research News In the future, could Alzheimer disease treatments come as an ointment, or a skin patch? That may not be as far out as it seems, with a new study published this week in PNAS online showing that mice produce amyloid-clearing antibodies after a
RESEARCH NEWS 2003-05-21 Research News After a tough year, during which believers in immunotherapy for Alzheimer’s disease have had to fend off vociferous criticism, the news now appears to pick up. In tomorrow’s Neuron, Swiss researchers announce that among the AD patients who r
CONFERENCE COVERAGE 2007-10-29 Conference Coverage On Saturday, 27 October, in Los Angeles, an unusual conference marked a paradigm shift in the Alzheimer disease movement, or so its organizers hope and vow. Put together jointly by Richard Bozanich (see ARF Q&A) and Jay Smith, two
RESEARCH NEWS 2008-07-02 Research News Flurizan has floundered in an 18-month Phase 3 clinical trial in patients with mild Alzheimer disease. According to a June 30 press release from Myriad Genetics, one of the sponsors of the drug, the study did not achieve statistical signific
COMMUNITY NEWS 2013-05-18 Community News Alzheimer's disease researchers expressed sadness this week at the sudden death of Larry Sparks, senior scientist at the Banner Sun Health Research Institute, Sun City, Arizona, at the age of 63. Sparks worked in Sun City from 1997. Sp
RESEARCH NEWS 2014-01-03 Research News In Alzheimer’s research, finding a way to safely lower Aβ levels in the human brain remains a central goal. Thus, scientists were excited by a 2010 Nature paper in which researchers led by Nobel laureate Paul Greengard at Rockefeller Univers
RESEARCH NEWS 2016-04-29 Research News Papers in the March 17 EMBO Molecular Medicine and the April 20 Neuron have reignited a simmering debate about the role of presenilin mutations in familial Alzheimer’s disease. Both studies dispute a claim made previously by Jie Shen, Ray Ke
RESEARCH NEWS 2016-06-10 Research News Presenilin 2 has long lived in the shadow of its sibling, presenilin 1. Either one can serve as the catalytic subunit of γ-secretase, but presenilin 1 has hogged much of the limelight, in part because many more pathogenic Alzheimer’s disease
RESEARCH NEWS 2017-02-15 Research News Merck dropped a Valentine’s Day downer announcing they will stop the EPOCH trial of verubecestat in mild to moderate Alzheimer’s disease. A prespecified interim analysis by an external data-monitoring committee gave the trial “virtually no
